Leukotriene B₄ and asthma

P E Christie, N C Barnes

Lipid derived mediators generated from arachidonic acid metabolism have attracted considerable interest as mediators of asthma. Arachidonic acid, a 20-carbon polyunsaturated fatty acid, is released from membrane phospholipases by the action of phospholipases under the influence of a variety of stimuli. The 5-lipoxygenase pathway generates the intermediate 5-HPETE which is reduced to 5-HETE or is converted to the unstable epoxide leukotriene A₄ (LTA₄). LTA₄ is acted on by an epoxide hydrolase to form leukotriene B₄ (LTB₄) or by a glutathione transferase to generate leukotriene C₄. LTC₄ is cleaved by gamma glutamyl transferase to generate leukotriene D₄ (LTD₄) and then a dipeptidase to form leukotriene E₄ (LTE₄). LTC₄, LTD₄, and LTE₄ comprise the cysteinyl leukotrienes previously recognised as slow-reacting substance of anaphylaxis (SRS-A).

Asthma is characterised by airways inflammation in which eosinophilic infiltration is prominent. There is a complex interaction between many mediators, cytokines, and cells. The role of cysteinyl leukotrienes (LTC₄, LTD₄, and LTE₄) in modulating and regulating this inflammation has been extensively studied and supported by their properties as potent bronchoconstrictors, ability to increase airway responsiveness, vascular permeability and mucus production. The recovery of cysteinyl leukotrienes from the bronchoalveolar lavage (BAL) fluid of asthmatic subjects and increased urinary excretion of LTE₄ during asthmatic attacks further supports a role for these as important mediators in asthma.

There is now considerable evidence that cysteinyl leukotriene receptor antagonists have effects in asthma. The role, if any, for LTB₄ in asthma is less clear.

Leukotriene biosynthesis occurs in a variety of cells (neutrophils, eosinophils, monocytes, macrophages, mast cells, basophils, and B lymphocytes). Eosinophils preferentially generate LTC₄ while peripheral blood neutrophils, alveolar macrophages, and monocytes generate mainly LTB₄. LTB₄ is also generated from eosinophils. The current evidence supports the cysteinyl leukotrienes as mediators in asthma and LTB₄ a mediator of greater significance in diseases where neutrophil inflammation predominates. However, the presence of neutrophils in some instances in asthma and the biological and physiological properties of LTB₄ mean that a role in asthma for LTB₄ remains a possibility.

LTB₄ is a potent pro-inflammatory mediator. Its activities include chemokinesis and chemotaxis of human neutrophils and eosinophils, chemokinesis of monocytes, aggregation of neutrophils, and enhanced expression of complement receptors on granulocytes. It induces release of lysosomal enzymes from neutrophils and augmentation of neutrophil adherence to endothelial cell monolayers. LTB₄ induced endothelial cell adhesions for neutrophils depend on increased CD11/CD18 expression on the neutrophil surface. LTB₄ causes release of enzymes from neutrophils and augments interleukin 6 (IL-6) production in human monocytes; it may modulate the production of other cytokines and also has effects on T lymphocyte proliferation. In vivo intradermal injection of LTB₄ promotes neutrophil infiltration into human skin. It activates not only neutrophils but also enhances mediator release from eosinophils. LT₄ is spasmodenic for smooth muscle; in the guinea pig this is indirectly through the stimulation of secondary cyclooxygenase synthesis although tachyphylaxis occurs rapidly. It is thought to have its chemotactic effect on neutrophils via a specific high affinity receptor site and at higher concentrations it induces neutrophil enzyme release, possibly via a low affinity receptor. LTB₄ receptors are also expressed on eosinophils and, when activated, may help regulate eosinophil numbers and function.

Inhalation of ozone in dogs induces airway hyperresponsiveness and airway neutrophilia as does inhalation of LTB₄. In the brown Norway rat allergen challenge resulted in an increased capacity of lung cells to synthesise LTB₄ from macrophages rather than eosinophils. Antigen induced airway eosinophilia in guinea pigs is decreased by an LTB₄ receptor antagonist. In man allergic challenge of atopic individuals causes an early increase in neutrophils but by 24 hours the eosinophil predominates.

In asthmatic and normal individuals cysteinyl leukotrienes are the predominant leukotriene recovered from BAL fluid. However, 20-hydroxyl LTB₄ (an oxidation product of LTB₄) has also been recovered in one study. Evidence against a fundamental role for LTB₄ comes from studies of inhaled LTB₄ in asthmatics when airway function or responsiveness are not affected despite the observation that intratracheal instillation of LTB₄ induces the recruitment of active neutrophils into BAL fluid in humans.

Studies of LTB₄ mediator release further provide contradictory evidence for a role for LTB₄ in asthma. Increased production of LTB₄ by neutrophils occurs in patients with allergic rhinitis and in asthmatic children or adults during exacerbations of asthma. Alveolar macrophages from wheezy infants release larger amounts of LTB₄ under resting conditions than do alveolar macrophages from control subjects. However, Restrick et al found a decreased synthesis of LTB₄ from alveolar macrophages obtained by BAL in asthmatic patients. LTB₄ may play a contributory role in nocturnal asthma. More neutrophils, eosinophils, LTB₄, and cysteinyl leukotrienes are recovered in BAL fluid at 0400 hours in subjects with nocturnal asthma than in those without nocturnal asthma. LTB₄ levels correlate significantly with nocturnal falls in forced expiratory vol-

Downloaded from http://thorax.bmj.com/ on October 20, 2017 - Published by group.bmj.com
umer in one second (FEV1). Treatment with the 5-lipoxygenase inhibitor zileuton results in decreased recovery of eosinophils from BAL fluid and a trend to improvement in the FEV1. After treatment with prednisolone pulmonary alveolar macrophage-stimulated production of LTB4 decreases with a reduction in neutrophil influx which correlates with an improvement in the nocturnal FEV1. One important contribution of LTb4 in asthma may be related to the considerable airway neutrophilia which predominates in sudden onset fatal asthma, suggesting that the neutrophil products released may be important in the underlying fatal pathology.

The assessment of drugs that antagonise the effects of cysteinyl leukotrienes or prevent their synthesis have demonstrated beneficial effects on asthma induced by antigens, exercise, and cold air and in clinical asthma. The lack of any clear difference between cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibitors would argue against an important role for LTb4 in asthma. To elucidate the role of LTb4 in asthma further specific leukotriene b4 receptor antagonists have now been synthesised.

In the paper by Evans et al in this issue of Thorax the authors report the first study of the effect of an LTb4 receptor antagonist, LY293111, in asthma. The role of LTb4 in the airway recruitment and activation of eosinophils and neutrophils following the late asthmatic response to allergen was determined by evaluating the effect of antagonism of LTb4 on lung function and the release of several cytokines and inflammatory mediators from the cell population in BAL fluid obtained 24 hours after allergen challenge. Treatment for seven days with LY293111 significantly decreased the numbers of neutrophils and the level of myeloperoxidase hours after allergen challenge in 12 mild asthmatic subjects with a demonstrable late asthmatic response (LAR). Active treatment reduced concentrations of LTb4 in the BAL fluid and also decreased levels of IL-8, a cytokine associated with neutrophil inflammation. It failed to have any effect on the numbers of eosinophils, macrophages, or lymphocytes in the BAL fluid. The other cytokines (IL-6, GM-CSF, TNFα) and inflammatory mediators (PGD2, PGE2, PGI2, TXB2) were unchanged by treatment although LTC4 was reduced, but not significantly. LY293111 did not alter either the size of the LAR or the allergen induced increase in bronchial hyperresponsiveness. From these findings the authors suggest an influence of LTb4 on neutrophil influx and activation in the airways following allergen challenge. The absence of physiological effects of pretreatment with LY293111 on allergen induced airway responses questions the functional role of the neutrophil in the pathophysiology of allergen induced asthma. The absence of an effect on eosinophil numbers suggests that LTb4 is not a major mediator of allergen induced eosinophil activity in human asthma, although a minor action of LTb4 on eosinophils cannot be excluded due to a small fall in BAL fluid levels of LTC4, a mediator released by eosinophils. LY293111 did not change the numbers of macrophages or lymphocytes in the BAL fluid. IL-8 is synthesised and released by several inflammatory cells within the airways including macrophages, lymphocytes, epithelial cells, and neutrophils. Although IL-8 levels fell with treatment there was no change in eosinophil numbers suggesting that IL-8, which acts as a potent chemoattractant and activator of neutrophils with lesser effects on eosinophils, was not a major contributory cytokine to eosinophil recruitment. The effect of an LTb4 antagonist on IL-8 levels suggests that leukotrienes may be involved with the modulation of cytokine production.

While such studies provide an important insight into the pathogenesis of asthma, further studies may elucidate a role for LTb4 in the clinical treatment of asthma. In addition to the potential therapeutic benefits of the LTb4 inhibitor LY293111 for patients with asthma, it would be of considerable interest to determine the effects that such agents might have on asthmatic responses to challenge with ozone and tolune disocyanate (TDI) which are characterised by an airway neutrophilia. The effects of an LTb4 receptor antagonist in respiratory diseases where LTb4 and neutrophils are major inflammatory mediators and cells – such as the adult respiratory distress syndrome, chronic bronchitis, bronchiectasis, cryptogenic fibrosing alveolitis, and cystic fibrosis – would be interesting to evaluate. Treatment aimed at interfering with the production or action of LTb4 may be beneficial in such respiratory diseases, although current evidence does not suggest an important role in asthma.

Correspondence to: Dr N C Barnes

Department of Respiratory Medicine, London Chest Hospital, Bonner Road, London E2 9JX, UK

23 Black PN, Fuller RW, Taylor GW, Barnes PJ, Dollery CT. Effect of inhaled leukotriene B4 alone and in combination with prostaglandin D2.
Leukotriene $B_4$ and asthma


Leukotriene B4 and asthma.

P. E. Christie and N. C. Barnes

Thorax 1996 51: 1171-1173
doi: 10.1136/thx.51.12.1171

Updated information and services can be found at:
http://thorax.bmj.com/content/51/12/1171.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/